Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Gyre Therapeutics (NASDAQ: GYRE) has announced the pricing of its public offering of 2,222,222 shares of common stock at $9.00 per share, aiming to raise approximately $20.0 million in gross proceeds. The underwriters have a 30-day option to purchase up to an additional 333,333 shares. The offering is expected to close around May 27, 2025.
The biotechnology company plans to use the proceeds to advance its Phase 2 clinical trial of F351 in MASH-associated liver fibrosis in the United States, fund research and development, manufacturing scale-up, and support working capital needs. Jefferies is serving as the lead book-running manager, with H.C. Wainwright & Co. as co-manager for the offering.
Gyre Therapeutics (NASDAQ: GYRE) ha annunciato il prezzo della sua offerta pubblica di 2.222.222 azioni ordinarie a 9,00 dollari per azione, con l'obiettivo di raccogliere circa 20,0 milioni di dollari di proventi lordi. Gli underwriter hanno un'opzione di 30 giorni per acquistare fino a ulteriori 333.333 azioni. La chiusura dell'offerta è prevista intorno al 27 maggio 2025.
La società biotecnologica intende utilizzare i proventi per avanzare la fase 2 della sperimentazione clinica di F351 nella fibrosi epatica associata a MASH negli Stati Uniti, finanziare la ricerca e sviluppo, l'aumento della produzione e supportare le esigenze di capitale circolante. Jefferies è il principale gestore dell'offerta, con H.C. Wainwright & Co. come co-manager.
Gyre Therapeutics (NASDAQ: GYRE) ha anunciado el precio de su oferta pública de 2.222.222 acciones ordinarias a 9,00 dólares por acción, con el objetivo de recaudar aproximadamente 20,0 millones de dólares en ingresos brutos. Los suscriptores tienen una opción de 30 días para comprar hasta 333.333 acciones adicionales. Se espera que la oferta cierre alrededor del 27 de mayo de 2025.
La compañía biotecnológica planea usar los fondos para avanzar en el ensayo clínico de fase 2 de F351 en fibrosis hepática asociada a MASH en Estados Unidos, financiar investigación y desarrollo, la ampliación de la producción y apoyar las necesidades de capital de trabajo. Jefferies actúa como gestor principal, con H.C. Wainwright & Co. como co-gestor de la oferta.
Gyre Therapeutics (NASDAQ: GYRE)는 보통주 2,222,222주를 주당 9.00달러에 공모하는 공모가를 발표했으며, 약 2,000만 달러의 총 수익을 목표로 하고 있습니다. 인수인들은 30일 동안 추가로 최대 333,333주를 매입할 수 있는 옵션을 보유하고 있습니다. 공모는 2025년 5월 27일경 마감될 예정입니다.
이 생명공학 회사는 미국 내 MASH 관련 간섬유증에 대한 F351 2상 임상시험을 진행하고, 연구개발, 제조 확대 및 운전자본 지원을 위해 자금을 사용할 계획입니다. Jefferies가 주간사로, H.C. Wainwright & Co.가 공동 주간사로 참여합니다.
Gyre Therapeutics (NASDAQ : GYRE) a annoncé le prix de son offre publique de 2 222 222 actions ordinaires à 9,00 $ par action, visant à lever environ 20,0 millions de dollars de produits bruts. Les souscripteurs disposent d'une option de 30 jours pour acquérir jusqu'à 333 333 actions supplémentaires. La clôture de l'offre est prévue aux alentours du 27 mai 2025.
La société biotechnologique prévoit d'utiliser les fonds pour faire progresser son essai clinique de phase 2 de F351 dans la fibrose hépatique associée au MASH aux États-Unis, financer la recherche et développement, l'augmentation de la production et soutenir les besoins en fonds de roulement. Jefferies agit en tant que chef de file, avec H.C. Wainwright & Co. en tant que co-gestionnaire de l'offre.
Gyre Therapeutics (NASDAQ: GYRE) hat den Preis für sein öffentliches Angebot von 2.222.222 Stammaktien zu je 9,00 USD bekanntgegeben und plant, rund 20,0 Millionen USD Bruttoerlös zu erzielen. Die Underwriter haben eine 30-tägige Option, bis zu weitere 333.333 Aktien zu erwerben. Der Abschluss des Angebots wird voraussichtlich um den 27. Mai 2025 erfolgen.
Das Biotechnologieunternehmen beabsichtigt, die Erlöse zur Weiterführung der Phase-2-Studie von F351 bei MASH-assoziierter Leberfibrose in den USA zu verwenden, sowie zur Finanzierung von Forschung und Entwicklung, Produktionsausweitung und zur Unterstützung des Betriebskapitals. Jefferies fungiert als Hauptbuchführer, H.C. Wainwright & Co. als Co-Manager.
- Secured $20.0 million in funding to advance clinical trials and R&D
- Strong institutional backing with Jefferies as lead book-running manager
- Proceeds will support Phase 2 clinical trial advancement and manufacturing scale-up
- Dilution of existing shareholders' value through issuance of 2.22M new shares
- Additional potential dilution if underwriters exercise their option for 333,333 shares
- Offering price of $9.00 may represent a discount to market price
Insights
Gyre secures $20M through public offering to advance MASH-related liver fibrosis trials and R&D initiatives.
Gyre Therapeutics has priced its underwritten public offering at
The pricing at
Notably, Jefferies is serving as lead book-running manager, with H.C. Wainwright & Co. as co-manager, bringing institutional backing to this offering. The proceeds will fund not only the MASH trial but also broader research and development activities, manufacturing scale-up, and general corporate operations.
For investors following fibrosis-focused biotechs, this capital infusion strengthens Gyre's financial position to advance its clinical programs through critical development stages. The funding comes at a pivotal time as the company progresses its Phase 2 clinical trial in MASH-associated liver fibrosis, a condition with significant unmet medical need and commercial potential in the metabolic disease space.
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of
Jefferies is acting as lead book-running manager for the offering and H.C. Wainwright & Co. is acting as co-manager for the offering.
Gyre intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and cash flows from operations, to advance its Phase 2 clinical trial of F351 in metabolic dysfunction-associated steatohepatitis (“MASH”)-associated liver fibrosis in the United States, for research and development, manufacturing and scale-up, as well as for working capital and general corporate purposes.
The shares of common stock described above are being offered pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) that was declared effective by the SEC on November 22, 2024. The offering of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: Gyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions with respect to the offering; and the expected use of net proceeds from the offering. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the offering; Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC.
Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com
FAQ
How much money is Gyre Therapeutics (GYRE) raising in its public offering?
What will Gyre Therapeutics use the proceeds from its $20M offering for?
When is GYRE's public offering expected to close?
Who are the underwriters for Gyre Therapeutics' public offering?
How many additional shares can the underwriters purchase in GYRE's offering?
